Press release
United States Glioblastoma Treatment Market Trends: Opportunities in Targeted Therapy, Immunotherapy & Precision Medicine By 2031 | Leading Companies -Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC,
Image credit goes to:researchgate.net
Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glioblastoma-treatment-market?oppratik
Recent Product launch in U.S Market-
✅ August 6, 2025 - Modeyso (Dordaviprone) by Jazz Pharmaceuticals received FDA accelerated approval in the U.S. for H3 K27M-mutated diffuse midline glioma, marking the first systemic therapy directly targeting this mutation in glioblastoma patients.
✅ August 25, 2025 - ANKTIVA NK-Cell Therapy (Investigational) by ImmunityBio demonstrated 100% disease control in 5 out of 5 recurrent glioblastoma patients during an early-phase clinical trial, with FDA submission expected soon.
Recent Product Launchi In Japan market-
✅Japan: In July 2025, Japanese regulator granted "SAKIGAKE" designation to a peptide vaccine for GBM in Japan.
Recent Mergers & Acquisitions (2025)
-In March 2025, Jazz Pharmaceuticals acquired Chimerix for $935 million, obtaining Modeyso (dordaviprone) which was later approved to be used in the U.S..
-Earlier, Merck & Co. had acquired Modifi Biosciences to develop glioblastoma-targeted therapy MOD-246, which targets temozolomide-resistant glioblastoma.
-There were no reported significant new M&As specific to glioblastoma in Japan within the past 5 months. There were, however, some oncology focused consolidations (such as Concentra Biosciences acquisition of Elevation Oncology in July 2025) supporting capital allocation towards innovation in neuro-oncology..
Recent Investments (May-October 2025)
-Alpheus Medical raised $52 million in Series B (May 2025) to develop its sonodynamic therapy (SDT) for patients with newly diagnosed GBM in North America.
-The Innovation GBM consortium has provided $170 million in total investment since 2023, with additional rounds in mid-2025 to support nine GBM-focused startups.
-A UK Government-backed £70 million initiative was announced in September 2025 to accelerate the clinical research phase of drug trials for glioblastoma in 2026.
Key Players-
Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries, Ltd., F. Hoffman-La Roche, Novartis AG and Pfizer.
Research Process:
Both primary and secondary data sources have been used in the global Glioblastoma Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=glioblastoma-treatment-market?oppratik
DataM Intelligence has published a new research report on "Glioblastoma Treatment Market Size 2025". The report explores comprehensive and insightful Information.The global glioblastoma treatment market report delivers a detailed analysis with 45 key tables, more than 41 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
Key Segments:
By Treatment Type- Chemotherapy, Immunotherapy, Electric-field therapy, Others
By Type of Molecule- Small Molecules, Biologics
By Route of Administration- Oral, Parenteral
By End-User- Hospitals, Clinics, Others
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
FDA and Regulatory Approvals (Recent Months)
August 6, 2025 - The Food and Drug Administration (FDA) approved Modeyso (Dordaviprone) for use in diffuse midline glioma with H3 K27M mutation (Jazz Pharmaceuticals).
January 2025 - The FDA also approved Novocure's Head Flexible Electrode Arrays, Optune Gio, for adult patients with glioblastoma.
April 2025 - Alpha Tau Medical received FDA Investigational Device Exemption (IDE) approval for the Alpha DaRT pilot study on patients with recurrent glioblastoma.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glioblastoma-treatment-market?oppratik
Latest News:
October 2025 - NBTS-funded UCLA research entered clinical trials addressing resistance mechanisms in glioblastoma.
August 2025 - ImmunityBio ANKTIVA NK-cell therapy showed complete disease control in recurrent GBM cases.
June 2025 - ASCO 2025 highlighted dual-target CAR-T therapies slowing GBM growth.
Impact of COVID-19 (Glioblastoma Market)
Delays in data resulted from disruptions to early-phase clinical trial enrollment due to nursing home lockdowns.
Rapid adoption of telemedicine and decentralized clinical trials improved follow-up care.
Post pandemic, there is a growing focus on domestic manufacturing and supply chain resiliency for oncology drugs.
FAQ's
Q1: What is the current size of the Glioblastoma Treatment Market?
A: The Glioblastoma Treatment Market stood at US$ 2.74 billion in 2024 and is set to experience remarkable growth, reaching US$ 5.77 billion by 2033
Q2: How fast is the Glioblastoma Treatment Market growing?
A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 8.7% from 2025 to 2033
Q3: Which regions are dominating the Glioblastoma Treatment Market and which are fastest-growing?
A: North America dominating the Glioblastoma Treatment market.
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?oppratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Glioblastoma Treatment Market Trends: Opportunities in Targeted Therapy, Immunotherapy & Precision Medicine By 2031 | Leading Companies -Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, here
News-ID: 4235391 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Japan Automotive Mechanical Testing Industry Sector to hit US$ 1,216.02 million …
Japan automotive mechanical testing market reached US$ 790.56 million in 2024 and is expected to reach US$ 1,216.02 million by 2032, growing at a CAGR of 5.53% during the forecast period 2025-2032.
DataM Intelligence has published a new research report on "Japan Automotive Mechanical Testing Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players…
United States Radiofrequency Ablation Devices Market to Reach USD 11.31 Billion …
The Global Radiofrequency Ablation Devices Market reached $5.63 billion in 2024 and is projected to grow to $13.54 billion by 2033, with a CAGR of 10.7% from 2025 to 2033.
This growth is mainly driven by the rising cases of chronic pain, cancer, and cardiac arrhythmias, along with the increasing demand for minimally invasive treatment methods. Improvements in radiofrequency ablation technology, such as AI-assisted systems and real-time imaging-guided devices, are…
Automotive Logistics Industry Sector | Future Trends & Growth Opportunities, Lea …
DataM Intelligence has published a new research report on "Automotive Logistics Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample PDF Of This Report…
United States Tyrosine Kinase Inhibitors Market to Reach USD 93.97 Billion by 20 …
The Global Tyrosine Kinase Inhibitors market reached US$ 51.03 billion in 2023, increased to US$ 53.99 billion in 2024, and is expected to hit US$ 93.97 billion by 2033, growing at a CAGR of 6.4% from 2025 to 2033.
This growth is driven by the rising cancer rates, greater use of precision oncology, and ongoing development in targeted drug creation. The increasing adoption of personalized medicine, new generation TKIs with…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
